CD47 and neoplasm: For example, the combination of the CD47 blocking antibody magrolimab with rituximab demonstrated clinical activity in patients with non-Hodgkin’s lymphomas and was the first clinical study to confirm the scientific rationale for myeloid immune checkpoint blockade in tumor patients (40).